| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/22/2004 | CA2492561A1 Treatment and prophylaxis with 4-1bb-binding agents |
| 01/22/2004 | CA2492554A1 Combination therapies with l-fmau for the treatment of hepatitis b virus infection |
| 01/22/2004 | CA2492391A1 Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| 01/22/2004 | CA2492387A1 Combination of an allosteric carboxylic of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| 01/22/2004 | CA2492374A1 Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea |
| 01/22/2004 | CA2492368A1 Compositions intended for the treatment of peripheral neuropathies, preparation thereof and uses of same |
| 01/22/2004 | CA2492355A1 Method for diagnosis of intestinal-type gastric tumors |
| 01/22/2004 | CA2492093A1 Topical treatment of skin diseases |
| 01/22/2004 | CA2492068A1 Assays for assembly of ebola virus nucleocapsids |
| 01/22/2004 | CA2492059A1 Combinations of drugs for the treatment of neoplasms |
| 01/22/2004 | CA2491924A1 Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs |
| 01/22/2004 | CA2491820A1 Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| 01/22/2004 | CA2491797A1 Gastrointestinal compositions |
| 01/22/2004 | CA2491721A1 Gastrointestinal compositions comprising gaba derivatives |
| 01/22/2004 | CA2491320A1 Methods and compositions for modulating t helper (th) cell development and function |
| 01/22/2004 | CA2491235A1 Chromosome 3, 5 and 11 genes involved in premature canities |
| 01/22/2004 | CA2490666A1 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| 01/21/2004 | EP1382969A1 Diagnosis and prevention of cancer cell invasion |
| 01/21/2004 | EP1382616A2 Pharmaceutical composition for use in the treatment of abnormalities associated with the activity of a human Y5-receptor |
| 01/21/2004 | EP1382606A2 8-azabicyclo[3.2.1]octane derivatives and their use as anticholinergics |
| 01/21/2004 | EP1382351A1 Combination therapy of agiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovasuclar disease |
| 01/21/2004 | EP1382346A1 Conditioned medium and diffusible biological product produced by incubating entrapped cells |
| 01/21/2004 | EP1382345A2 Uses of inhibitors of hemostasis |
| 01/21/2004 | EP1382343A1 Combination therapy to treat hepatitis B virus |
| 01/21/2004 | EP1382339A1 Compositions containing pyrrolo [2,3-d] pyrimidine derivatives |
| 01/21/2004 | EP1382337A1 Novel formulation containing paroxetine |
| 01/21/2004 | EP1381839A2 Method of imaging cell death in vivo |
| 01/21/2004 | EP1381684A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 01/21/2004 | EP1381678A2 Nucleic acid modification enzymes |
| 01/21/2004 | EP1381626A2 Human transporters and ion channels |
| 01/21/2004 | EP1381623A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 01/21/2004 | EP1381598A1 Novel tyrosine kinase inhibitors |
| 01/21/2004 | EP1381590A1 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| 01/21/2004 | EP1381431A1 Aromatase inhibition to enhance assisted reproduction |
| 01/21/2004 | EP1381415A1 Method of intradermally injecting substances |
| 01/21/2004 | EP1381408A2 Modular infusion device and method |
| 01/21/2004 | EP1381397A2 Stabilisation of radiopharmaceutical compositions using a hydrophilic thioether or a hydrophilic 6-hydroxy chroman |
| 01/21/2004 | EP1381394A2 Biomaterials comprising a melanocyte stimulating hormone (msh), and method of forming |
| 01/21/2004 | EP1381386A2 Novel mixtures of microbial enzymes |
| 01/21/2004 | EP1381384A2 COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFa |
| 01/21/2004 | EP1381382A2 Methods and compositions for the treatment of diseases of the eye |
| 01/21/2004 | EP1381377A2 A composition including a platelet activating factor inhibitor and an antioxidant which interferes with the arachidonic acid cascade |
| 01/21/2004 | EP1381372A2 Substituted tetracycline compounds as synergistic antifungal agents |
| 01/21/2004 | EP1381371A2 Hormone replacement therapy |
| 01/21/2004 | EP1381368A2 Compositions containing imidazotriazinone for nasal application |
| 01/21/2004 | EP1381366A2 Indole, azaindole and related heterocyclic amidopiperazine derivatives |
| 01/21/2004 | EP1381361A1 Combination therapy comprising glucose reabsorption inhibitors and ppar modulators |
| 01/21/2004 | EP1381359A1 Aurones as telomerase inhibitors |
| 01/21/2004 | EP1381354A2 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders |
| 01/21/2004 | EP1381346A2 Aerosol compositions containing formoterol for delivery to the lungs via nebulization |
| 01/21/2004 | EP1381345A2 Delivery of disease control in aquaculture and agriculture using microbes containing bioactive proteins |
| 01/21/2004 | EP1191942B1 Use of antileukoprotease for the treatment of endometriosis |
| 01/21/2004 | EP1131083B1 Use of growth hormone releasing compounds and their antagonists for the treatment of tumors |
| 01/21/2004 | EP1128826B1 Chromone enteric release formulation |
| 01/21/2004 | EP0981366B1 Selective mmp inhibitors having reduced side-effects |
| 01/21/2004 | EP0914124B1 ANTITHROMBOTIC AND ANTIATHEROGENIC PHARMACEUTICAL COMPOSITION INCLUDING A THIENOPYRIDINE DERIVATIVE AND AN HMG-CoA-REDUCTASE INHIBITOR |
| 01/21/2004 | EP0842276B1 Method for reproducing in vitro the rna-dependent rna polymerase and terminal nucleotidyl transferase activities encoded by hepatitis c virus (hcv) |
| 01/21/2004 | EP0734263B1 ALPHAvBETA3 INTEGRIN AS A PREDICTOR OF ENDOMETRIOSIS |
| 01/21/2004 | CN1469876A Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| 01/21/2004 | CN1469875A Pyrazole compounds useful as protein kinase inhibitors |
| 01/21/2004 | CN1469874A Pyrazole compounds useful as protein kinase inhibitors |
| 01/21/2004 | CN1469873A Piperidine compounds as anti-allergic |
| 01/21/2004 | CN1469871A Substituted dipeptides as growth hormone secretagogues |
| 01/21/2004 | CN1469759A Implants with a phosphazene-containing coating |
| 01/21/2004 | CN1469748A Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors |
| 01/21/2004 | CN1469746A A retroviral immunotherapy |
| 01/21/2004 | CN1469739A Method for modulating bladder function |
| 01/21/2004 | CN1469736A Use of a porous carrier |
| 01/21/2004 | CN1469735A Liposomal formulation of mitoxantrone |
| 01/21/2004 | CN1469711A Treatment of helicobacter with isothiocyanates |
| 01/21/2004 | CN1468594A Composition containing at least one oxidative sensitive hydrophilic active ingredient through at least one maleic anhydride copolymer stabilization |
| 01/20/2004 | US6680372 Antibodies specific for growth differentiation factor-7 |
| 01/20/2004 | US6680341 Stable pharmaceutical formulation comprising a HMG-CoA reductase inhibitor |
| 01/20/2004 | US6680340 Anti-hypercholesterolemic drug combination |
| 01/20/2004 | US6680336 Cyclic nucleotide phosphodiesterases inhibitors; antiinflammatory agents; 2,3-dioxy-4-pyrrole substituted phenyl derivatives |
| 01/20/2004 | US6680310 Methods for preventing antipsychotic-induced weight gain |
| 01/20/2004 | US6680309 Administering hypocalcemic hydroxyvitamin d compound having ahydrocarbon moiety at the c-24 position as anticarcinogenic agent |
| 01/20/2004 | US6680306 Method for enhancing the effectiveness of cancer therapies |
| 01/20/2004 | US6680305 Physiologically acceptable aqueous solutions and methods for their use |
| 01/20/2004 | US6680303 3′,5-difluoro-2′,3′-didehydropyrimidine nucleosides and methods of treatment therewith |
| 01/20/2004 | US6680298 Administering polypeptide to increase serum levels; dietetics, hypoglycemic agents; cardiovascular, autoimmune, kidney, metabolic and nervous system disorder treatment |
| 01/20/2004 | US6680173 Diagnosis of tauopathies |
| 01/20/2004 | US6680171 Drug screening, genetic engineering |
| 01/20/2004 | US6680062 Anti-irritating rosacea treatment |
| 01/20/2004 | US6680054 Macromolecular neuraminidase-binding compounds |
| 01/20/2004 | CA2383742C Silver-based antimicrobial compositions |
| 01/20/2004 | CA2310290C Composition for and method of preventing or treating breast cancer |
| 01/20/2004 | CA2241247C Archaeosomes, archaeosomes containing coenzyme q10, and other types of liposomes containing coenzyme q10 as adjuvants and as delivery vehicles |
| 01/15/2004 | WO2004005881A2 Methods for identification of compounds modulating insulin resistance |
| 01/15/2004 | WO2004005544A2 Marker genes for determining renal toxicity |
| 01/15/2004 | WO2004005538A1 Method of screening anticancer agent |
| 01/15/2004 | WO2004005529A2 GEF-H1b: BIOMARKERS, COMPLEXES, ASSAYS AND THERAPEUTIC USES THEREOF |
| 01/15/2004 | WO2004005476A2 Nucleic acid compositions for stimulating immune responses |
| 01/15/2004 | WO2004005474A2 A robust, inducible cardiac preferred expression system for transgenesis |
| 01/15/2004 | WO2004005323A2 Affinity small molecules for the epo receptor |
| 01/15/2004 | WO2004005286A2 Viral inhibitors |
| 01/15/2004 | WO2004005285A1 New quinuclidine amide derivatives |
| 01/15/2004 | WO2004005266A1 Oxazole derivatives and their use as insulin sensitizers |
| 01/15/2004 | WO2004005262A2 New neuropeptide y y5 receptor antagonists |
| 01/15/2004 | WO2004005258A1 Di-aryl-substituted-ethane pyridone pde4 inhibitors |